The Centers for Medicare & Medicaid Services Innovation Center (CMMI) announced new flexibilities and adjustments to its current and future alternative payment models in response to the COVID-19 Public Health Emergency (PHE). Of note for the cancer community, CMMI made changes to the Oncology Care Model, such as payment methodology, quality reporting, and the timeline.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
On June 3, 2020, ASCO President Dr. Lori J. Pierce released a statement "Responding to Racism and Health Inequality as a Cancer Care Community".
Providers have until June 3, 2020, to apply for the Provider Relief Fund, which has been allocated by the U.S. Department of Health and Human Services (HHS) for general distribution to Medicare facilities and providers impacted by COVID-19.
A MedWatch Safety Alert was added to the FDA Medical Device Safety webpage titled STERRAD Sterilization Systems: Letter to Health Care Providers.
On May 29, 2020, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
On May 29, 2020, the Food and Drug Administration approved atezolizumab in combination with bevacizumab (TECENTRIQ® and AVASTIN®, Genentech Inc.) for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
On May 29, ASCO's CancerLinQ® announced it had launched a new platform for CancerLinQ Discovery®, its de-identified real-world cancer data product for researchers across the cancer community.
On May 26, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
In an open letter, the Regulatory Relief Coalition (RRC) called on all health plans in the United States to suspend prior authorization requirements for both COVID-19 and non-COVID-19-related services during the novel coronavirus pandemic.
On May 22, 2020, the Food and Drug Administration approved brigatinib (ALUNBRIG®, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA®, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.
ASCO released the ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemic, which provides detailed guidance to oncology practices on the immediate and short-term steps that could be taken to help protect the safety of patients and healthcare staff before resuming more routine care operations during the COVID-19 public health crisis.
On May 18, 2020, the Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK genomic tumor aberrations.
A new infographic in the May 2020 print and online issues of JCO Oncology Practice (JCO OP) outlines paths to implementing the American Society of Clinical Oncology’s (ASCO) Patient-Centered Oncology Payment (PCOP) model—an alternative payment model designed to support transformation in cancer care delivery and reimbursement while ensuring that patients with cancer have access to high-quality care. Along with the infographic, the latest issue of JCO OP features an in-depth overview of recent changes to PCOP and two invited commentaries on the model.
On May 15, 2020, the Food and Drug Administration approved ripretinib (QINLOCK™, Deciphera Pharmaceuticals, LLC.), for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.